ARS Pharmaceuticals, Inc Financial Flexibility Index
ARS Pharmaceuticals, Inc financial flexibility index. ARS Pharmaceuticals, Inc (SPRY) has a Financial Flexibility Index of -0.20x as of December 2025. Free cash flow of $-43.48 Million (operating CF $-43.48 Million minus capex $0.00) represents 0% of total liabilities ($213.39 Million). See SPRY free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Financial Flexibility Index of ARS Pharmaceuticals, Inc (2018–2025)
Financial flexibility index of ARS Pharmaceuticals, Inc from 2018 to 2025. Historical Financial Flexibility Index trend for ARS Pharmaceuticals, Inc across 8 annual periods. Check cash flow quality index of ARS Pharmaceuticals, Inc to evaluate the quality of earnings relative to operating cash generation.
ARS Pharmaceuticals, Inc Financial Flexibility Index by Year (2018–2025)
ARS Pharmaceuticals, Inc financial flexibility index by year from 2018 to 2025. Year-by-year free cash flow to debt coverage for ARS Pharmaceuticals, Inc. For the full cash flow conversion analysis, see SPRY cash flow metrics.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -0.80x | $-170.53 Million | $-170.87 Million | $213.39 Million | ▼ -634.3% |
| 2024 | 0.15x | $14.11 Million | $13.55 Million | $94.36 Million | ▲ +100.6% |
| 2023 | -24.34x | $-59.09 Million | $-59.27 Million | $2.43 Million | ▼ -421.7% |
| 2022 | -4.66x | $-39.88 Million | $-40.08 Million | $8.55 Million | ▼ -2370.5% |
| 2021 | -0.19x | $-17.51 Million | $-17.56 Million | $92.72 Million | ▼ -176.5% |
| 2020 | 0.25x | $9.99 Million | $9.07 Million | $40.46 Million | ▲ +127.9% |
| 2019 | -0.88x | $-18.80 Million | $-18.90 Million | $21.25 Million | ▲ +49.6% |
| 2018 | -1.76x | $-16.43 Million | $-16.88 Million | $9.35 Million | — |